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Summary 
 
Background: Questions remain about the shape of the dose-response relationship between 
body mass index (BMI) and pancreatic cancer risk, possible confounding by smoking, and 
differences by gender or geographic location. Whether abdominal obesity increases risk is 
unclear.  
 
Methods: We conducted a systematic review and meta-analysis of prospective studies of the 
association between BMI, abdominal fatness and pancreatic cancer risk and searched PubMed 
and several other databases up to January 2011. Summary relative risks were calculated using 
a random effects model. 
 
Results: Twenty-three prospective studies of BMI and pancreatic cancer risk with 9504 cases 
were included. The summary relative risk (RR) for a 5 unit increment was 1.10 (95% CI: 
1.07-1.14, I
2
=19%) and results were similar when stratified by gender and geographic 
location. There was evidence of a nonlinear association, pnonlinearity=0.005, however, among 
non smokers there was increased risk even within the “normal” BMI range. The summary RR 
for a 10 cm increase in waist circumference was 1.11 (95% CI: 1.05-1.18, I
2
=0%) and for a 
0.1 unit increment in waist-to-hip ratio was 1.19 (95% CI: 1.09-1.31, I
2
=11%).  
 
Conclusions: Both general and abdominal fatness increases pancreatic cancer risk. Among 
non smokers risk increases even among persons within the “normal” BMI range.  
 
Key words: Body mass index, waist circumference, waist-to-hip ratio, pancreatic cancer, 
systematic review, meta-analysis.  
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Introduction 
Pancreatic cancer is the 9
th
 most common cause of cancer with 277 000 new cases diagnosed 
in 2008 worldwide, accounting for about 2.2% of all cancer cases (1). Pancreatic cancer 
patients have a very low survival, on average only 6 months after diagnosis, because there are 
few early symptoms and the disease is usually diagnosed in the later stages. Currently there 
are no established methods of screening for early detection, thus, at present primary 
prevention by altering modifiable risk factors will probably be the most effective way of 
reducing the pancreatic cancer burden.  
 Epidemiological studies have suggested that overweight and obesity are associated 
with increased pancreatic cancer risk. The evidence that body fatness increases pancreatic 
cancer risk was considered conclusive in the World Cancer Research Fund/American Institute 
for Cancer Research (WCRF/AICR) report from 2007 (2). However, more recent reviews of 
the evidence suggested an increased risk with higher body mass index (BMI, weight in 
kilograms divided by height squared in metres) among women, but not among men (3), and in 
addition, there were inconsistencies in the results by geographic location (3). The exact shape 
of the dose-response relationship between body mass index and pancreatic cancer risk has not 
been clearly defined. Smoking is an established risk factor for pancreatic cancer and a 
potentially important confounding factor of the association between BMI and pancreatic 
cancer risk. Smokers tend to have a lower BMI than non smokers and residual confounding 
by smoking may attenuate or distort the dose-response relationship between BMI and 
pancreatic cancer risk. The best way to avoid residual confounding by smoking is to restrict 
the analyses to non smokers or never smokers, however, because pancreatic cancer is a 
relatively uncommon type of cancer, individual studies may have had limited statistical power 
to examine the association among non smokers, thus combining results from several studies in 
a meta-analysis will increase statistical power to detect significant associations. Hence, we 
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explored whether smoking may have confounded the association between BMI and pancreatic 
cancer risk. Abdominal obesity may be more strongly associated with insulin resistance than 
peripheral obesity (4), but there have been relatively few studies of waist circumference and 
waist-to-hip ratio as measures of abdominal fatness in relation to pancreatic cancer risk. A 
number of additional large cohort studies have been published since the WCRF/AICR report 
from 2007 (5-17), thus, we conducted an updated meta-analysis of BMI, waist circumference 
and waist-to-hip ratio and pancreatic cancer risk with the aim to clarify whether body fatness 
is associated with pancreatic cancer in both men and women and in European and Asian 
populations as well. In addition, we wanted to clarify the dose-response relationship between 
BMI, waist circumference and waist-to-hip ratio and pancreatic cancer risk by conducting 
nonlinear dose-response analyses and by restricting the analysis to studies among non 
smokers or never smokers.  
 
Methods 
 
Search strategy 
Initially relevant studies of anthropometric measures and pancreatic cancer risk were 
identified by searching several databases up to December 2005, including Pubmed, Embase, 
CAB Abstracts, ISI Web of Science, BIOSIS, LILACS, Cochrane library, CINAHL, AMED, 
National Research Register, and In Process Medline. However, because all the relevant 
studies were identified by the PubMed search, a change to the protocol was made and in the 
updated searches only Pubmed was searched from 1
st
 January 2006 to 31
st
 of January 2011. A 
prespecified protocol was followed for the review 
(http://www.dietandcancerreport.org/downloads/SLR_Manual.pdf) and we used standard 
criteria for meta-analyses of observational studies (18). In addition, we also searched the 
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reference lists of all the studies that were included in the analysis and the reference lists of 
published meta-analyses (3;19;20). 
 
Study selection 
Prospective cohort studies, case-cohort studies, or nested case-control studies of the 
association between BMI, waist circumference, or waist-to-hip ratio and pancreatic cancer 
risk incidence or mortality were included. Relative risk estimates (hazard ratio, risk ratio) had 
to be available with the 95% confidence intervals in the publication and for the dose-response 
analysis, a quantitative measure of intake and the total number of cases and person-years had 
to be available in the publication. We identified 48 potentially relevant full-text publications 
(5-17;21-56). We excluded fourteen duplicate publications (13;25;29;30;32;33;40;41;43;45-
47;49;51;52) four publications which did not present risk estimates (23;24;26;39) and one 
publication using <3 categories for categorisation of BMI (27) leaving 29 publications for 
inclusion in the analysis (5-12;14-17;21;22;28;31;34-38;42;44;48;50;53-56). Results from 
two overlapping publications were included only in subgroup analyses stratified by sex (42) 
or smoking (44) but not in the overall analyses, because the superseding publications did not 
present sex-specific results (5) or results stratified by smoking in enough detail to be included 
(16). 
 
Data extraction 
We extracted from each study: The first author’s last name, publication year, country where 
the study was conducted, the study name, follow-up period, sample size, gender, age, number 
of cases, assessment method of anthropometric factors (measured vs. self-reported), RRs and 
95% CIs, and variables adjusted for in the analysis. Several reviewers at the University of 
Leeds conducted the search and data extraction of articles published up to December 2005, 
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during the systematic literature review for the WCRF/AICR report 
(http://www.dietandcancerreport.org/downloads/SLR/Pancreas_SLR.pdf). The search and 
data extraction from January 2006 and up to January 2011 was conducted by one author 
(D.A) and was checked for accuracy by one author (T. N). 
 
Statistical analysis 
Summary RRs and 95% CIs for a 5 unit increment in BMI, 10 cm increment in waist 
circumference and for a 0.1 unit increment in waist-to-hip ratio were estimated using a 
random effects model (57). The average of the natural logarithm of the RRs was estimated 
and the RR from each study was weighted by the inverse of its variance. A two-tailed p<0.05 
was considered statistically significant. If studies reported results separately for men and 
women we combined the sex-specific estimates using a fixed-effects model to generate an 
estimate for both genders combined. We conducted separate analyses for pancreatic cancer 
incidence and mortality.  
The method described by Greenland and Longnecker (58) was used for the dose–
response analysis and study-specific slopes (linear trends) and 95% CIs were computed from 
the natural logs of the RRs and CIs across categories of anthropometric measures. The method 
requires that the distribution of cases and person-years or non-cases and the RRs with the 
variance estimates for at least three quantitative exposure categories are known. We estimated 
the distribution of cases or person-years in studies that did not report these, but reported the 
total number of cases and person-years (Online supplement 1). The mean BMI, waist 
circumference of waist-to-hip ratio level in each category was assigned to the corresponding 
relative risk for each study and for studies that reported these measures by ranges we 
estimated the mean in each category using the method described by Chene and Thompson 
(59). A potential nonlinear dose-response relationship between BMI, waist circumference and 
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waist-to-hip ratio and pancreatic cancer was examined by using fractional polynomial models 
(60). We determined the best fitting second order fractional polynomial regression model, 
defined as the one with the lowest deviance. A likelihood ratio test was used to assess the 
difference between the nonlinear and linear models to test for nonlinearity (60). 
Subgroup and meta-regression analyses were conducted to investigate potential 
sources of heterogeneity and heterogeneity between studies was quantitatively assessed by the 
Q test and I
2
 (61) Small study effects, such as publication bias, were assessed by inspecting 
the funnel plots for asymmetry and with Egger’s test (62) and Begg’s test (63), with the 
results considered to indicate small study effects when p<0.10. Sensitivity analyses excluding 
one study at a time were conducted to clarify whether the results were simply due to one large 
study or a study with an extreme result.  
 
Role of the funding source 
The funding source had no role in the study design, collection, analysis and interpretation of 
the data, in the writing of the report or in the decision to submit the paper for publication.  
 
Results 
We identified twenty-four prospective studies (23 publications) (5-12;14-
17;21;22;28;31;34-38;42;44) that were included in the analyses of BMI and pancreatic cancer 
incidence (Supplementary Table 1, Figure 1). Two of these publications were only included in 
subgroup analyses of sex (42) and stratified by smoking (44) as they overlapped with two 
more recent publications (5;16). Seven cohort studies (16;48;50;53-56) were included in the 
analysis of pancreatic cancer mortality (Supplementary Table 2). Five cohort studies (four 
publications) (5;10;12;36) were included in the analysis of waist circumference and four 
cohort studies (5;10;12;37) were included in the analysis of waist-to-hip ratio and pancreatic 
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cancer incidence. Characteristics of the included studies are provided in Supplementary Table 
1 and Supplementary Table 2. Most of the studies were from Europe and the US and used 
self-reported weight and height (Supplementary Table 1 and Supplementary Table 2).  
 
BMI  
Twenty three prospective studies (21 publications) (5-12;14-17;21;22;28;31;34-38) 
were included in the overall dose-response analysis of BMI and pancreatic cancer incidence 
and included a total of 9504 cases among 5,037,555 participants. Ten studies were from the 
US, ten were from Europe, and the remaining three were from Asia (Supplementary Table 1). 
The summary RR for a 5 unit increment in BMI was 1.10 (95% CI: 1.07-1.14), with no 
significant heterogeneity, I
2
=19%, p=0.20 (Figure 2a). The summary RR was similar among 
men and women, summary RR= 1.10 (95% CI: 1.04-1.16, I
2
=46%, pheterogeneity=0.03) for 
women (7-12;16;17;28;34-38;42) and 1.13 (95% CI: 1.04-1.22, I
2
=42%, pheterogeneity=0.05) for 
men (6-11;14;17;28;34-38), respectively (Table 1). Although there was no statistically 
significant difference in the association between never or non smokers(5-7;10;44) and ever 
smokers (5-7;10) in stratified analyses the association was restricted to never and non smokers 
(Table 1). In sensitivity analyses excluding one study at a time, the summary RR in the 
overall analysis ranged from 1.09 (95% CI: 1.06-1.12) when the Cancer Prevention Study 2 
Nutrition Cohort was excluded to 1.11 (95% CI: 1.08-1.14) when the Multiethnic Cohort 
Study was excluded. There was no evidence of small study effects with Egger’s test, p=0.36, 
or with Begg’s test, p=0.27 and when visually inspected the funnel plot showed no sign of 
asymmetry.  
To address the question of reverse causality, e.g. whether prediagnostic disease may 
have influenced BMI, we restricted the analyses to the six studies (5;8;10;11;34;44) that 
provided results with exclusion of early follow-up (first 1-4 years of follow-up), but the 
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results were similar, summary RR=1.11 (95% CI: 1.05-1.18, I
2
=35%, pheterogeneity=0.18). 
Further restricting the analysis to the four studies (5;8;11;44) which excluded at least the first 
two years of follow-up did not materially change the results, summary RR=1.13 (95% CI: 
1.05-1.21, I
2
=26%, pheterogeneity=0.25) (results not shown). 
The results were in general consistent across subgroups of duration of follow-up, 
geographic location, number of cases, adjustment for most confounding factors and 
adjustment for diabetes (Table 1). Only in the subgroups of studies with and without 
adjustment for physical activity and red meat was there some evidence of heterogeneity 
(pheterogeneity=0.03 for both comparisons), with a stronger association among studies that 
adjusted for physical activity (n=4), but no association among studies that adjusted for red 
meat (n=2), however, the number of studies in these subgroup analyses was very low. We also 
conducted further subgroup analyses within strata of gender to investigate potential sources 
for the observed heterogeneity for men and women when analyzed separately, but only in the 
analysis among women stratified by adjustment for meat intake was there some evidence of 
heterogeneity (p=0.009). An inverse association was found in the two studies that adjusted for 
meat intake (summary RR=0.86, 95% CI: 0.75-0.99), but a positive association was observed 
in studies that did not adjust for meat intake (summary RR=1.10, 95% CI: 1.06-1.15) (results 
not shown).  
There was evidence of a nonlinear association between BMI and pancreatic cancer 
risk, pnonlinearity=0.005 (Figure 2b), with the lowest risk among persons with a BMI around 21 
and with the most pronounced increase in risk among persons with a BMI above 35. The 
association between BMI and pancreatic cancer risk appeared to be linear when we further 
restricted the nonlinear analysis to studies of never and non smokers (6;7;10), pnonlinearity=0.61, 
however, the shape of the dose-response curve was steeper and there was evidence of an 
increase in risk even among persons with a BMI in the “normal” range (BMI 21<25) (Figure 
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3a). In contrast, there was no evidence of an association between BMI and increased 
pancreatic cancer risk when we restricted the nonlinear analysis to ever smokers (Figure 3b) 
(7;10).  
Seven cohort studies (16;48;50;53-56) were included in the BMI and pancreatic cancer 
mortality analysis and included 8869 deaths among 2,537,564 participants. Three of the 
studies were from the US, two from Europe and two from Asia (Supplementary Table 2). The 
summary RR was 1.16 (95% CI: 0.98-1.36) and there was moderate heterogeneity, I
2
=56%, 
pheterogeneity=0.04 (Figure 4a). The summary RR ranged from 1.06 (95% CI: 1.01-1.11) when 
the Cancer Prevention Study 2 was excluded to 1.21 (95% CI: 0.97-1.49) when the Million 
Women’s study was excluded. The Cancer Prevention Study 2 (55) also explained all the 
heterogeneity and when excluded, I
2
=0%, pheterogeneity=0.43. There was no evidence of small 
study effects with Egger’s test, p=0.43, or with Begg’s test, p=0.76. There was evidence that 
the association between BMI and pancreatic cancer mortality was nonlinear, 
pnonlinearity=0.0001, and the risk was most pronounced above a BMI of 35 (Figure 4b).  
 
Waist circumference 
Five cohort studies (four publications) (5;10;12;36) were included in the analysis of 
waist circumference and pancreatic cancer risk and included 949 cases among 787,356 
participants. Three studies were from Europe and two from the US (Supplementary Table 1). 
The summary RR for a 10 cm increase in waist circumference was 1.11 (95% CI: 1.05-1.18) 
with no evidence of heterogeneity, I
2
=0%, p=0.74 (Figure 5a). The summary RR ranged from 
1.11 (95% CI: 1.04-1.17) when the Cohort of Swedish Men was excluded to 1.14 (95% CI: 
1.06-1.22) when the Women’s Health Initiative was excluded. The summary estimate was 
similar among men (summary RR=1.13, 95% CI: 0.89-1.44, I
2
=61%, p=0.11), and women 
(summary RR=1.14, 95% CI: 1.02-1.28, I
2
=29%, p=0.24) p for heterogeneity=0.59 (results 
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not shown). There was no evidence of small study effects with Egger’s test, p=0.11, or with 
Begg’s test, p=0.22. There was no evidence of a nonlinear association between waist 
circumference and pancreatic cancer risk, pnonlinearity=0.28 (Figure 3c).  
 
Waist-to-hip ratio 
Four cohort studies (5;10;12;37) were included in the analysis of waist-to-hip ratio and 
pancreatic cancer risk and included 1047 cases among 878,137 participants. Three were from 
the US and one from Europe (Supplementary Table 1). The summary RR for a 0.1 unit 
increment in waist-to-hip ratio was 1.19 (95% CI: 1.09-1.31) with no significant heterogeneity 
I
2
=11%, p=0.34 (Figure 5b). The summary RR ranged from 1.15 (95% CI: 1.04-1.27) when 
the Women’s Health Initiative was excluded to 1.24 (95% CI: 1.12-1.37) when the Iowa 
Women’s Health Study was excluded. The summary estimate was similar among men 
(summary RR=1.20, 95% CI: 0.96-1.50, I
2
=not calculable, n=1) and women (summary 
RR=1.17, 95% CI: 1.00-1.36, I
2
=41%, p=0.18), p for heterogeneity=0.89 (results not shown). 
There was no evidence of small study effects with Egger’s test, p=0.50, or with Begg’s test, 
p=0.73. There was no evidence of a nonlinear association between waist circumference and 
pancreatic cancer risk, pnonlinearity=0.29 (Figure 3d). 
 
Discussion 
 
In this meta-analysis we found evidence of an increased risk of pancreatic cancer with higher 
BMI and a similar association with measures of abdominal obesity, such as waist 
circumference and waist-to-hip ratio.  
However, to our knowledge for the first time in a meta-analysis of BMI and pancreatic 
cancer, we have found a potential nonlinear association between BMI and pancreatic cancer 
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risk. The most pronounced increase in risk was observed at a BMI above 35, however, when 
we further restricted the analyses to studies among non and never smokers the shape of the 
curve became initially steeper and there was evidence of an increased risk even within the 
high “normal” range of BMI. In contrast, there was no association between BMI and 
pancreatic cancer risk among ever smokers. Thus, residual confounding from smoking may 
have distorted the dose-response relationship between BMI and pancreatic cancer risk in the 
overall analysis. The positive associations between waist circumference and waist-to-hip ratio 
and pancreatic cancer risk appeared to be linear. We found little evidence of heterogeneity in 
the overall analyses of BMI, waist circumference, and waist-to-hip ratio and pancreatic cancer 
incidence, while in the analysis of BMI and pancreatic cancer mortality the moderate 
heterogeneity that was present was explained by a large American study (55). Our analysis 
confirms the hypothesis that both overall body fatness and abdominal fatness are associated 
with increased risk of pancreatic cancer and provide further support for the findings from a 
recent meta-analysis (3) and the WCRF/AICR report from 2007 (2). However, with a larger 
number of studies, we also found significant associations among both men and women and 
among American, European and Asian studies and there was no evidence of a difference 
between the summary estimates for these subgroups, confirming the importance of body 
weight control for pancreatic cancer prevention in diverse populations and among both 
genders. Two pooled analyses (64;65) and a meta-analysis (3) have previously reported 
somewhat stronger associations among women than among men, while our meta-analysis and 
another pooled analysis (66) showed similar results in men and women. The difference 
between our findings and the previous analyses may relate to the larger number of studies 
now available and therefore more statistical power to detect an association also among men. 
In addition, a higher percentage of men than women were current or former smokers in one of 
the pooled analyses (65), thus residual confounding from smoking may have to a larger 
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degree obscured an existing association among men than among women. In another pooled 
analysis, the risk estimates for a BMI≥35 were similar for men and women when excluding 
current and former smokers (RR=1.65, 95% CI: 0.96-2.84 for men vs. RR=1.65, 95% CI: 
1.13-2.40 for women) (64). In most of the studies data on smoking was collected only at 
baseline and it is possible that residual confounding from changes in smoking over time still 
may be present in the analysis of nonsmokers, however, this would most likely result in 
underestimation of the association between BMI and pancreatic cancer risk.  
 Our meta-analysis has some limitations which may affect the interpretation of the 
results. The main limitation is the low number of cohort studies available reporting on waist 
circumference and waist-to-hip ratio which limited our possibility to conduct subgroup and 
sensitivity analyses of these measures (including stratification by smoking status). In addition, 
we were not able to investigate whether the association between abdominal fatness and 
pancreatic cancer risk was independent of BMI because of the few studies that had explored 
this question. It is possible that the positive association between BMI or abdominal fatness 
and pancreatic cancer risk could be due to unmeasured or residual confounding by other 
lifestyle factors, such as lower physical activity or dietary factors. The results persisted when 
stratified by adjustment for physical activity, diabetes and smoking and also when restricted 
to never smokers. Diabetes may, however, also be considered an intermediate variable since 
BMI partly could increase pancreatic cancer risk through an effect on diabetes, but from our 
subgroup analyses it seems that there is still an association between higher BMI and increased 
pancreatic cancer risk which is independent of diabetes. Overweight and obesity is typically 
associated with unhealthy diets but very few studies adjusted for intake of alcohol, red meat, 
fruit and vegetables and energy intake, thus these subgroup analyses are difficult to interpret. 
Measurement errors in the assessment of height and weight may have influenced our results. 
Most of the studies relied on self-reported height and weight, and although there may be some 
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underreporting of weight and overreporting of height, most studies have found a high 
correlation between self-reported and measured height and weight (67;68). In addition, the 
results were very similar when studies were stratified by whether weight and height was 
measured or self-reported, lending further credibility to self-reported anthropometric 
measures. Weight was collected at baseline and not during follow-up in most of the studies, 
thus it is possible that these measures may not reflect usual adult weight so there may be some 
misclassification of long-term exposure. Pancreatic cancer is usually diagnosed in the later 
stages and is frequently associated with profound weightloss, thus it is also possible that use 
of baseline data in this case may provide more valid results than if the data were updated 
through follow-up because of less influence of prediagnostic weightloss. The subgroup 
analyses of BMI and pancreatic cancer among non and never and ever smokers were based on 
a limited number of studies and we can therefore not rule out the possibility that some degree 
of reporting bias may be present (e.g. more studies that found a difference between smokers 
and non smokers reported stratified results than studies which did not find a difference) and 
may have led to exaggerated findings in this subgroup. Nevertheless, a pooled analysis also 
reported stronger results among never smokers compared than among smokers (64), thus 
reporting bias is not likely to be the sole explanation for this finding. Although meta-analyses 
of published literature may be susceptible to small study effects, we found no evidence of 
small study effects with either Egger’s test or with Begg’s test or when visually inspecting the 
funnel plots. 
 Our meta-analysis also has several strengths. Because we based our analysis on 
prospective studies, recall bias and selection bias are not likely to explain our findings. In 
addition, prospective studies avoid the reliance on use of proxy respondents which have been 
used extensively in case-control studies of pancreatic cancer due to the poor survival rates. 
Our meta-analysis included a large number of cohort studies with relatively long follow-up 
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and included 9504 cases among 5037555 participants in the BMI analysis, so we had 
statistical power to detect moderate or weak associations. We also had statistical power to 
detect significant associations in various subgroups of populations including men and women, 
Asian, American and European studies, by duration of follow-up and number of cases. The 
results were generally robust to the influence of single studies. In addition, we investigated 
whether reverse causation (e.g. prediagnostic disease might have influenced BMI) could have 
biased the results by restricting the analyses to studies which excluded early follow-up, 
however, the risk estimates were similar in these analyses. Further, we explored, to our 
knowledge for the first time in a meta-analysis, a nonlinear association between BMI, waist 
circumference and waist-to-hip ratio and pancreatic cancer. Our results underscore the 
importance of body weight control in pancreatic cancer prevention in diverse populations and 
irrespective of gender, but they suggest that avoiding abdominal fatness also may be 
important. In addition, with decreasing prevalence of smoking in several populations it is 
important that future epidemiological studies report more detailed results (e.g. stratified by 
smoking status), both to avoid selective reporting of results and to avoid residual confounding 
which can result in underestimation of the impact of body fatness on pancreatic cancer risk.  
  
In summary, our meta-analysis, which is the most up to date review of the evidence, 
confirms the hypothesis that increased BMI and abdominal obesity are associated with 
increased pancreatic cancer risk. The association between elevated BMI and increased 
pancreatic cancer risk is observed in both men and women and in North American, European 
and Asian studies. A nonlinear association is observed in the overall analysis with increased 
risk above a BMI of 25, but most pronounced above a BMI of 35, however, in analyses 
restricted to non smokers there is evidence of increased risk even among persons in the 
“normal” range of BMI (21<25). Thus, our results provide further support for previous 
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recommendations to be as lean as possible within the normal range of BMI, but also suggest 
that avoiding abdominal obesity is likely to be important in the prevention of pancreatic 
cancer.  
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Table 1: Subgroup analyses of BMI and pancreatic cancer 
 BMI 
 n RR (95% CI) I
2
 (%) Ph
1 
Ph
2
 
All studies 23 1.10 (1.07-1.14) 19.3 0.20  
Sex      
    Men  14 1.13 (1.04-1.22) 45.6 0.03 0.76 
    Women 15 1.10 (1.04-1.16) 41.8 0.05 
Assessment of weight/height      
    Measured  7 1.11 (1.07-1.15) 0 0.58 0.90 
    Self-reported 14 1.12 (1.05-1.20) 40.2 0.06 
    Measured and self-reported 2 1.07 (0.95-1.21) 0 0.49 
Duration of follow-up      
    <10 yrs follow-up 11 1.09 (1.03-1.15) 38.6 0.09 0.42 
     ≥10 yrs follow-up 12 1.12 (1.08-1.17) 0 0.65 
Geographic location       
    Europe 10 1.10 (1.06-1.15) 0 0.60 0.96 
    America 10 1.10 (1.03-1.17) 45.0 0.06 
    Asia 3 1.15 (1.08-1.22) 0 0.55 
Number of cases      
    Cases <299 14 1.15 (1.09-1.22) 0 0.59 0.14 
    Cases 300<500 5 1.07 (0.99-1.16) 45.5 0.12 
    Cases ≥500 4 1.09 (1.04-1.14) 40.1 0.17 
Smoking status     0.16 
    Never/non smoker 5 1.11 (1.04-1.17) 0 0.55 
    Ever smoker 4 1.03 (0.95-1.10) 0 0.93 
Adjustment for confounders 
Alcohol  Yes  4 1.14 (0.96-1.37) 0 0.56 0.70 
No  19 1.10 (1.06-1.14) 28.1 0.12 
Smoking  
 
Yes  19 1.11 (1.06-1.17) 29.5 0.20 0.50 
No  4 1.09 (1.04-1.14) 0 0.76 
Diabetes Yes  12 1.12 (1.05-1.20) 46.8 0.04 0.87 
No  11 1.11 (1.07-1.14) 0 0.78 
Physical activity  
 
Yes  4 1.26 (1.09-1.46) 16.8 0.31 0.03 
No  19 1.09 (1.06-1.12) 0 0.48 
Red, processed meat Yes  2 0.96 (0.86-1.07) 0 0.69 0.03 
24 
 
No  21 1.11 (1.08-1.14) 4.7 0.40 
Fruit and vegetables Yes 1 1.06 (0.65-1.70)   0.86 
No  22 1.10 (1.07-1.14) 22.9 0.16 
Energy intake Yes  3 1.10 (0.89-1.36) 84.6 0.002 0.58 
No  20 1.10 (1.07-1.14) 0 0.81 
n denotes the number of risk estimates 
1
 P for heterogeneity within each subgroup, 
 
2
 P for heterogeneity between subgroups with meta-regression analysis  
25 
 
Supplementary Table 1: Prospective studies of body mass index, waist circumference and waist-to-hip ratio and 
pancreatic cancer incidence  
 
Author, 
publication 
year, country/ 
region 
Study name Follow-up 
period 
Exclusion of 
early follow-
up 
Study 
size, 
gender, 
age, 
number 
of cases 
Assessment 
of weight 
and height 
Exposure  Description of quantiles of 
categories 
RR (95% CI) Adjustment for confounders 
Andreotti G et 
al, 2010, USA 
Agricultural 
Health Study 
1993/97 – 
2005, 10 
years 
follow-up 
No  39628 
men and 
28319 
women, 
age <40-
70 years: 
45/21 
cases 
 
Self-reported BMI, men 
 
 
 
BMI, women 
 
 
18.5-24.9 
25-29.9 
30-34.9 
Per 1 unit 
18.5-24.9 
25-29.9 
30-34.9 
Per 1 unit 
1.00 
1.11 (0.54-2.27) 
1.06 (0.42-2.65) 
0.99 (0.92-1.07)  
1.00 
1.30 (0.43-3.90) 
2.48 (0.79-7.83) 
1.06 (0.98-1.15)  
Men: age, diabetes 
Women: age, race 
Stevens RJ et 
al, 2009, UK 
The Million 
Women Study 
1996/2001
-
2006/2007, 
7.2 years 
follow-up  
Yes, first 2 
and first 4 
years 
excluded in 
sensitivity 
analyses 
1290000 
women, 
age 50-
64 years: 
1338 
cases 
 
Self-reported BMI 
 
 
 
 
 
BMI, all data 
BMI, excluding first 
2 years of follow-up 
BMI, excluding first 
4 years of follow-up 
<22.5 
22.5<25.0 
25.0<27.5 
27.5<30.0 
30.0<32.5 
≥32.5 
≥25 vs. <25 
≥25 vs. <25 
 
≥25 vs. <25 
1.02 (0.88-1.16) 
1.00 (0.89-1.12) 
0.99 (0.88-1.11) 
1.17 (0.98-1.40) 
1.27 (1.003-1.61) 
1.42 (1.12-1.80) 
1.14 (1.02-1.28) 
1.17 (1.04-1.33) 
 
1.12 (0.96-1.29) 
Age, region, socioeconomic 
status, height 
Reeves GK et 
al, 2007, UK 
The Million 
Women Study 
1996/2001 
– 
2003/2004, 
5.4 years 
follow-up 
Yes, first 2 
years 
excluded in 
sensitivity 
analyses 
1222630 
women, 
age 50-
64 years: 
305 cases 
(never 
smokers) 
Self-reported BMI, never smokers 
BMI, excluding first 
2 years of follow-up 
Per 10 units 
Per 10 units 
1.26 (0.94-1.69) 
1.28 (1.03-1.58) 
Age, geographical region, 
socioeconomic status, age at 
1
st
 birth, parity, smoking 
status, alcohol intake, physical 
activity 
Johansen D et 
al, 2009, 
Sweden 
The Malmo 
Preventive 
Project 
1974/1992 
– 2004, 
22.1 years 
follow-up 
No 
 
33346 
men and 
women, 
mean age 
50/44 
years: 
187 cases 
Measured  BMI <20 
20<25 
25<30 
≥30 
Per 1 unit 
0.84 (0.44-1.61) 
1.00 
0.83 (0.60-1.16) 
1.38 (0.83-2.28) 
1.04 (0.995-1.08) 
Age, sex, smoking status, 
Mm-Mast category 
Meinhold CL 
et al, 2009, 
Finland 
ATBC Cancer 
Prevention 
Study 
1985/88 – 
2004, 19.4 
years 
follow-up 
 
Yes, first 5 
years 
excluded in 
sensitivity 
analyses (not 
shown) 
27035 
smoking 
men, age 
50-69 
years: 
305 cases 
Measured  BMI 
 
 
 
23.1 
27.0 
31.5 
36.9 
Continuous  
1.00 
0.97 (0.76-1.24) 
1.03 (0.72-1.47) 
1.42 (0.69-2.93) 
1.01 (0.94-1.08) 
Age, cigarettes per day, years 
of smoking, total energy, 
diabetes 
Luo J et al, 
2008, USA 
Women’s 
Health 
Initiative 
1993/98-
2005, 7.7 
years 
follow-up 
Yes, first 2 
years 
excluded in 
senstivity 
analyses 
138503 
women, 
age 50-
79 years: 
251 cases 
 
Measured  BMI 
 
 
 
 
Waist circumference 
 
 
 
 
 
<22.0 
22-24.9 
25-29.9 
30-34.9 
≥35.0 
70.5 cm 
78.0 
85.0 
92.4 
105.0 
Per 10 cm 
0.8 (0.5-1.2) 
1.0 
0.9 (0.6-1.2) 
1.1 (0.7-1.5) 
0.8 (0.5-1.3) 
1.0 
1.1 (0.7-1.7) 
1.0 (0.7-1.6) 
1.4 (0.9-2.0) 
1.1 (0.7-1.6) 
1.05 (0.95-1.15) 
Age, different treatment 
assignments in clinical trials, 
smoking status, diabetes 
26 
 
WHR 
 
 
 
 
 
WHR, excluding first 
2 years 
0.72 
0.77 
0.80 
0.84 
0.91 
Per 0.1 units 
0.91 vs. 0.72 
1.0 
1.2 (0.8-1.9) 
1.1 (0.7-1.7) 
1.1 (0.7-1.7) 
1.7 (1.1-2.6)  
1.27 (1.07-1.50) 
1.6 (1.0-2.6) 
Jee SH et al, 
2008, Korea 
National 
Health 
Insurance 
Corporation 
Study 
1992/95 - , 
10.8 years 
follow-up 
Yes, first 2 
years 
excluded in 
analyses, 
first 5 years 
excluded in 
sensitivity 
analyses (not 
shown) 
1213829 
men and 
women, 
age 30-
95 years: 
1860/791 
cases 
 
Measured  BMI, men 
 
 
 
 
BMI, women 
<20.0 
20-22.9 
23.0-24.9 
25.0-29.9 
≥30.0 
<20.0 
20-22.9 
23.0-24.9 
25.0-29.9 
≥30.0 
0.87 (0.71-1.08) 
1.01 (0.87-1.16) 
1.00 
1.06 (0.90-1.24) 
1.34 (0.75-2.38) 
0.88 (0.62-1.24) 
1.09 (0.84-1.40) 
1.00 
1.35 (1.05-1.74) 
1.80 (1.14-2.86)  
Age, smoking status 
Stolzenberg-
Solomon R et 
al, 2008, USA 
NIH-AARP 
Diet and 
Health Study 
1995/96 – 
2000, ~5 
years 
follow-up 
Yes, first 
year 
excluded in 
analysis 
495035 
men and 
women, 
age 50-
71 years: 
654 cases 
 
Self-reported BMI 
 
 
 
 
BMI, never smokers 
or former smoker quit 
10+ yrs ago 
 
 
BMI, current or 
former smoker quit 
<10 yrs ago 
 
 
 
Waist, men 
 
 
 
 
WHR 
 
 
 
 
Waist, women 
 
 
 
WHR 
18.5<25.0 
25.0-29.9 
30.0-34.9 
≥35 
Per unit  
18.5<25.0 
25.0-29.9 
30.0-34.9 
≥35 
Per unit 
18.5<25.0 
25.0-29.9 
30.0-34.9 
≥35 
Per unit 
<88.9 cm 
88.9<93.3 
93.3<98.4 
98.4<106.0  
≥106.0 
<0.90 
0.90<0.93 
0.93<0.96 
0.96<1.00 
≥1.00 
<74.9 cm 
74.9<83.2 
83.2<92.1 
≥92.1 
<0.76 
0.76<0.81 
0.81<0.86 
≥0.86 
1.00 
1.26 (1.05-1.52) 
1.20 (0.94-1.52) 
1.45 (1.04-2.02)  
1.02 (1.00-1.04) 
1.00 
1.45 (1.15-1.84) 
1.37 (1.01-1.85) 
1.70 (1.14-2.53)  
1.02 (1.01-1.04) 
1.00 
0.99 (0.74-1.34) 
0.95 (0.63-1.44) 
1.09 (0.60-1.97) 
1.00 (0.98-1.03) 
1.00 
1.11 (0.70-1.75) 
0.95 (0.61-1.48) 
1.14 (0.74-1.76) 
1.07 (0.69-1.64) 
1.00 
1.00 (0.61-1.63) 
0.97 (0.59-1.58) 
1.20 (0.74-1.92) 
1.34 (0.86-2.08) 
1.00 
1.79 (0.92-3.47) 
1.99 (1.04-3.80) 
2.52 (1.33-4.77)  
1.00 
1.20 (0.66-2.18) 
1.22 (0.68-2.20) 
1.19 (0.66-2.15) 
Age, sex, smoking, race, 
diabetes 
Luo J et al, 
2007, Japan 
Japan Public 
Health Center-
based 
Prospective 
Study 
1990 - 
2003 
1993 – 
2003, 11.7 
years 
follow-up 
 
Yes, first 4 
years 
excluded in 
sensitivity 
analyses 
47499 
men and 
52171 
women, 
age 40-
69 years: 
128/96 
cases 
 
Self-reported 
and 
measured in 
subset 
(32470 
participants) 
BMI, men 
 
 
BMI, men, excluding 
first 4 years 
BMI, women 
 
 
BMI, men, excluding 
14-<21 
21-<25 
25-40 
25-40 vs. 14-<21 
 
14-<21 
21-<25 
25-40 
25-40 vs. 14-<21 
1.4 (0.8-2.5) 
1.0 
0.7 (0.4-1.1) 
0.7 (0.4-1.2)  
 
0.7 (0.4-1.3) 
1.0 
1.1 (0.7-1.6) 
1.2 (0.7-1.9) 
Age, smoking status, pack-
years, history of diabetes, 
leisure-time physical activity, 
study area, alcohol intake, 
history of cholelithiasis 
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first 4 years  
Nothlings U et 
al, 2007, USA 
Multiethnic 
Cohort Study 
1993/96 – 
2002, 7.5 
years 
follow-up 
Yes, first 2 
years 
excluded in 
sensitivity 
analyses (not 
shown), 
results 
reported to 
be similar 
77255 
men and 
90175 
women, 
age 45-
75 years: 
237/235 
cases 
Self-reported BMI, men 
 
 
BMI, women 
 
 
BMI, men, never 
smokers 
 
BMI, women, never 
smokers 
 
BMI, men, ever 
smokers 
 
BMI, women, ever 
smokers 
<25 
25<30 
≥30 
<25 
25<30 
≥30 
<25 
25<30 
≥30 
<25 
25<30 
≥30 
<25 
25<30 
≥30 
<25 
25<30 
≥30 
1.00 
0.99 (0.74-1.33) 
1.51 (1.02-2.26)  
1.00 
0.80 (0.59-1.09) 
0.65 (0.43-0.99)  
1.00 
1.14 (0.67-1.94) 
1.93 (0.91-4.08) 
1.00 
0.95 (0.61-1.48) 
0.61 (0.31-1.21) 
1.00 
0.91 (0.64-1.18) 
1.29 (0.80-2.07) 
1.00 
0.67 (0.44-1.03) 
0.66 (0.39-1.11) 
Age, ethnicity, smoking 
status, pack-years of smoking, 
family history of pancreatic 
cancer, history of diabetes 
mellitus, energy intake, intake 
of red meat, processed meat, 
physical activity 
Verhage BA et 
al, 2007, 
Netherlands 
Netherlands 
Cohort Study 
1986-1999, 
13.3 years 
follow-up 
Yes, first 2 
and 5 years 
excluded in 
sensitivity 
analyses (not 
shown), 
results 
reported to 
be similar 
Case-
cohort: 
4774 
men and 
women, 
age 55-
69 years: 
446 cases 
 
 
 
Self-reported BMI, men 
 
 
 
 
 
BMI, women 
<23 
23<25 
25<27 
27<30 
≥30 
Per unit 
<23 
23<25 
25<27 
27<30 
≥30 
Per unit 
1.10 (0.72-1.69) 
1.00 
0.93 (0.61-1.39) 
1.17 (0.75-1.81) 
2.69 (1.47-4.92)  
1.05 (0.99-1.12) 
1.02 (0.66-1.58) 
1.00 
1.69 (1.11-2.58) 
1.41 (0.89-2.25) 
1.31 (0.74-2.31)  
1.04 (1.00-1.08) 
Age, smoking, number of 
cigarettes per day, number of 
years smoked, history of 
diabetes, history of 
hypertension 
Samanic C et 
al, 2006, 
Sweden 
The Swedish 
Construction 
Worker’s 
Study 
1971-1999, 
19 years 
follow-up 
Yes, 
stratified 
analyses by 
<5, 5-9.9, 
10-14.9 and 
≥15 years 
follow-up 
(not shown), 
results 
reported to 
be similar 
362552 
men, age 
18-67 
years: 
698 cases 
147881 
Never-
smokers: 
126 cases 
Measured  BMI 
 
 
BMI, never smokers 
 
 
25.0 
25.0-29.9 
≥30.0 
25.0 
25.0-29.9 
≥30.0 
1.00 
0.95 (0.82-1.12) 
1.16 (0.87-1.53) 
1.00 
1.22 (0.83-1.79) 
1.80 (1.01-3.19)  
Age, calendar year, relative to 
normal weight subjects 
 
 
Berrington de 
Gonzalez AB 
et al, 2006, 
Europe (EPIC) 
European 
Prospective 
Investigation 
into Nutrition 
and Cancer 
1991/2000 
– 2004, 6.5 
years 
follow-up 
Yes, first 2 
years 
excluded in 
sensitivity 
analyses 
438405 
men and 
women, 
age 19-
84 years: 
324 cases 
Measured 
and self-
reported 
BMI 
 
 
 
 
 
 
 
BMI, excluding first 
2 years of follow-up 
Waist circumference 
 
 
 
<20 
20-22.9 
23-24.9 
25-26.9 
27-29.9 
30-34.9 
≥35.0 
per 5 kg/m
2 
per 5 kg/m
2 
 
<88/<73 cm m/w 
88-94/73-79 
94-101/79-88 
≥101/≥88 
0.67 (0.33-1.37) 
1.00 
0.99 (0.69-1.41) 
0.82 (0.56-1.19) 
0.76 (0.50-1.16) 
1.16 (0.77-1.76) 
1.19 (0.64-2.23)  
1.09 (0.95-1.24)  
1.14 (0.97-1.33) 
 
1.00 
0.89 (0.61-1.30) 
1.08 (0.75-1.54) 
1.14 (0.79-1.63) 
Age, sex, country, smoking, 
diabetes 
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Waist circumference, 
excluding first 2 
years of follow-up 
WHR 
 
 
 
 
WHR, excluding first 
2 years of follow-up 
per 10 cm 
per 10 cm 
 
 
0.90/0.75 m/w 
0.90-0.94/0.75-0.79 
0.94-0.98/0.79-0.84 
≥0.98/≥0.84 
per 0.1 units 
per 0.1 units 
1.13 (1.01-1.26) 
1.21 (1.07-1.37) 
 
 
1.00 
0.96 (0.65-1.41) 
1.05 (0.72-1.53) 
1.33 (0.93-1.92)  
1.24 (1.04-1.48) 
1.36 (1.11-1.66) 
Lukanova A et 
al, 2006, 
Sweden 
Northern 
Sweden 
Health and 
Disease 
Cohort 
1985-2003, 
8.2 years 
follow-up 
Yes, first 
year 
excluded in 
sensitivity 
analyses (not 
shown), 
results 
reported to 
be similar 
33424 
men and 
35362 
women, 
age 29-
61 years: 
24/41 
cases 
 
Measured  BMI, men 
 
 
BMI, women 
18.5-23.4 
23.5-25.3 
25.4-27.6 
18.5-22.1 
22.2-24.2 
24.3-27.0 
≥27.1 
1.00 
0.87 (0.32-2.37) 
0.61 (0.20-1.75) 
1.00 
0.71 (0.25-1.97) 
0.98 (0.39-2.55) 
1.23 (0.53-3.10) 
Age, calendar year, smoking 
Patel AV et al, 
2005, USA 
Cancer 
Prevention 
Study 2 – 
Nutrition 
Cohort 
1992-1999, 
7 years 
follow-up 
 
Yes, first 2 
years 
excluded in 
sensitivity 
analyses (not 
shown) 
145627 
men and 
women, 
age 50-
74 years: 
242 cases 
 
Self-reported BMI 
 
  
<25  
25-30 
≥30 
 
1.00 
1.03 (0.76-1.38) 
2.08 (1.48-2.93)  
 
Age, smoking status, years 
since quitting smoking, family 
history of pancreatic cancer,  
history of gallbladder disease, 
diabetes, height, total caloric 
intake, physical activity 
Sinner PJ et al, 
2005, USA 
Iowa 
Women’s 
Health Study 
1986-2001, 
15 years 
follow-up 
Yes, first 2 
years 
excluded in 
sensitivity 
analyses (not 
shown) 
38002 
women, 
age 55-
69 years: 
209 cases 
Self-reported BMI 
 
 
WHR 
 
 
<25.0 
25.0-29.9 
≥30 
0.335-0.7951 
0.7952-0.8693 
0.8694-2.8361 
1.00 
0.94 (0.69-1.29) 
1.14 (0.81-1.62) 
1.00 
0.86 (0.61-1.21) 
1.12 (0.81-1.55) 
Age, smoking status, 
multivitamin use 
Larsson SC et 
al, 2005, 
Sweden 
Swedish 
Mammograph
y Cohort 
Study 
1997-2004, 
6.8 years 
follow-up 
Yes, first 
year 
excluded in 
sensitivity 
analyses (not 
shown) 
37147 
women, 
mean age 
62 years: 
61 cases 
 
Self-reported BMI 
 
 
 
 
Waist circumference 
 
 
 
 
<20.0 
20.0-24.9 
25.0-29.9 
≥30 
Per 1 unit 
<76 cm 
76-81 
82-89 
≥90 
Per 20 cm 
0.76 (0.28-2.59) 
1.00 
1.57 (0.87-2.81) 
1.48 (0.60-3.62)  
1.04 (0.97-1.11) 
1.00 
0.94 (0.34-2.58) 
1.77 (0.74-4.22) 
1.46 (0.58-3.66) 
1.32 (0.73-2.37) 
Age, education, physical 
activity, cigarette smoking, 
alcohol consumption, 
diabetes, height,  
Larsson SC et 
al, 2005, 
Sweden 
Cohort of 
Swedish Men 
1997-2004, 
6.8 years 
follow-up 
 
Yes, first 
year 
excluded in 
sensitivity 
analyses (not 
shown) 
45906 
men, 
mean age 
60 years: 
75 cases 
 
Self-reported BMI 
 
 
 
 
Waist circumference 
 
 
 
 
<20.0 
20.0-24.9 
25.0-29.9 
≥30 
Per 1 unit 
<90 
90-94 
95-101 
≥102 
Per 20 cm 
1.54 (0.35-6.66) 
1.00 
1.06 (0.62-1.82) 
2.08 (1.02-4.25)  
1.06 (0.99-1.14) 
1.00 
1.15 (0.59-2.25) 
1.59 (0.87-2.93) 
1.72 (0.93-3.20)  
1.74 (1.00-3.01) 
Age, education, physical 
activity, cigarette smoking, 
alcohol consumption, 
diabetes, height,  
Kuriyama S et 
al, 2005, Japan 
Miyagi 
Prefecture 
Cohort Study 
 
1984 – 
1992, 7.6 
years 
follow-up 
No  12485 
men and 
15054 
women, 
age ≥40 
years: 
31/33 
Self-reported BMI, women 
 
 
BMI, men 
18.5-24.9 
25-27.4 
27.5-29.9 
18.5-24.9 
25-27.4 
27.5-29.9 
1.00 
0.63 (0.22-1.83) 
1.41 (0.56-3.51) 
1.00 
0.40 (0.10-1.72) 
1.38 (0.40-4.73) 
Age, smoking status, alcohol 
drinking, meat, fish, fruits, 
green or yellow vegetables, 
bean-paste soup, type of 
health insurance 
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cases 
Rapp K et al, 
2005, Austria 
 
The 
Vorarlberg 
Health 
Monitoring 
and Promotion 
Program 
1985/2001 
– 2002, 9.9 
years 
follow-up  
Yes, first 
year 
excluded in 
analysis 
67447 
men and 
78484 
women, 
mean age 
42 years: 
64/65 
cases 
 
Measured  BMI, men 
 
 
BMI, women 
 
 
18.5-24.9 
25.0-29.9 
≥30 
18.5-24.9 
25.0-29.9 
≥30 
1.00 
1.29 (0.73-2.37) 
2.34 (1.17-4.66)  
1.00 
0.87 (0.49-1.53) 
1.42 (0.76-2.68) 
Age, smoking status, 
occupational group 
Isaksson B, 
2002, Sweden 
Cohort of 
Swedish 
Twins 
1961/1967 
– 1997, 16 
years 
follow-up 
No  21884, 
median 
age 56 
years: 
176 cases 
Self-reported BMI  
 
18.5 
18.5-24.99 
25-30 
≥30 
2.30 (0.93-5.71) 
1.00 
1.36 (0.99-1.88) 
0.56 (0.20-1.52) 
Age, sex, cigarette smoking 
Michaud DS 
et al, 2001, 
USA 
Nurses’ 
Health Study 
1976-1996, 
20 years 
follow-up 
 
Yes, first 4 
years 
excluded in 
sensitivity 
analyses 
117041 
women, 
age 30-
55 years: 
210 cases 
Self-reported BMI 
 
 
 
 
BMI, excluding first 
4 years of follow-up 
<23.0 
23.0-24.9 
25.0-26.9 
27.0-29.9 
≥30.0 
≥30.0 vs. <23.0 
1.00 
1.09 (0.79-1.49) 
1.29 (0.92-1.80) 
1.30 (0.91-1.87) 
1.72 (1.19-2.48)  
1.94 (1.26-2.98) 
Age, height, pack-years of 
smoking, diabetes, 
cholecystectomy 
Michaud DS 
et al, 2001, 
USA 
Health 
Professionals 
Follow-up 
Study 
1986-1998, 
12 years 
follow-up 
 
Yes, first 4 
years 
excluded in 
sensitivity 
analyses 
46648 
men, age 
40-75 
years: 
140 cases 
Self-reported BMI 
 
 
 
 
BMI, excluding first 
4 years of follow-up 
<23.0 
23.0-24.9 
25.0-26.9 
27.0-29.9 
≥30.0 
≥30.0 vs. <23.0 
1.00 
1.09 (0.79-1.49) 
1.29 (0.92-1.80) 
1.30 (0.91-1.87) 
1.72 (1.19-2.48)  
2.03 (0.90-4.57) 
Age, height, pack-years of 
smoking, diabetes, 
cholecystectomy 
Shibata et al, 
1994 
California, 
USA 
Leisure World 
Cohort Study 
1981/1985 
– 1990, 7.2 
years 
follow-up 
No  13979 
elderly 
persons, 
mean age 
75/74 
years 
men/wo
men: 65 
cases 
Self-reported BMI Low 
Medium 
High 
1.00 
0.96 (0.50-1.84) 
1.23 (0.66-2.28) 
Age, sex, cigarette smoking 
Friedman et 
al, 1993, USA 
Multiphase 
Check-up 
Study 
1964-1988, 
≈12 years 
follow-up 
No  Nested 
case-
control 
study:  
452 cases 
2687 
controls 
Age 15-
94 years 
Measured  BMI Per 1 unit 
 
1.02 (1.00-1.04) Age, gender, examination site, 
date of first check-up 
 
 
 
 
 
 
 
 
 
30 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Table 2: Prospective studies of body mass index and pancreatic cancer mortality 
 
Author, 
publication 
year, country/ 
region 
Study name Follow-up 
period 
Exclusion 
of early 
follow-up 
Study size, 
gender, age, 
number of 
cases 
Assessment 
of weight 
and height 
Exposure  Description of quantiles of 
categories 
RR (95% CI) Adjustment for confounders 
Nakamura K 
et al, 2011, 
Japan 
Takayama 
study 
1992-1999, 
6.9 years 
follow-up 
No  
 
30826, age 
≥35 years: 
33/19 m/f 
deaths 
 
Self-reported BMI, men 
 
 
BMI, women 
21.3 
>21.3-23.6 
>23.6 
20.7 
>20.7-23.0 
>23.0 
1.00 
0.55 (0.23-1.32) 
0.59 (0.23-1.50)  
1.00 
0.37 (0.08-1.77) 
1.42 (0.52-3.85)  
Age, smoking status, diabetes 
mellitus 
Arnold LD et 
al, 2009, USA 
Cancer 
Prevention 
Study 2 
1984-2004, 
20 yrs 
follow-up 
Yes, first 2 
years 
excluded 
48525 
blacks: 360 
deaths  
1011864 
whites: 5883 
deaths 
Age ≥45 yrs 
 
Self-reported BMI, blacks 
 
 
 
BMI, whites 
<18.5 
18.5<25.0 
25.0<30.0 
≥30.0 
<18.5 
18.5<25.0 
25.0<30.0 
≥30.0 
0.44 (0.11-1.77) 
1.00 
0.89 (0.70-1.14) 
1.06 (0.80-1.42) 
0.93 (0.75-1.16) 
1.00 
1.15 (1.08-1.22) 
1.40 (1.28-1.52) 
Age, sex, diabetes, family 
history of pancreatic cancer, 
cholecystectomy 
Batty GD et 
al, 2009, UK 
The Whitehall 
Study 
1967/70 –,  
up to 38 
yrs follow-
up 
 
No  17898 men, 
age 40-69 
years: 163 
deaths 
 
Measured  BMI 1 
2 
3 
Per 2.98 units 
1.00 
1.02 (0.69-1.50) 
1.18 (0.79-1.75) 
1.03 (0.87-1.23) 
Age, smoking, plasma 
cholesterol, physical activity, 
socioeconomic status, 
DM/blood glucose, marital 
status, forced expiratory 
volume in 1 sec, height, 
diastolic and systolic blood 
pressure 
Stevens RJ et 
al, 2009, UK 
The Million 
Women’s 
Study 
1996/2001
-
2006/2007, 
8.9 years 
follow-up 
No  1290000 
women, age 
50-64 years: 
1710 deaths 
 
Self-reported BMI 
 
 
 
<22.5 
22.5<25.0 
25.0<27.5 
27.5<30.0 
30.0<32.5 
≥32.5 
1.08 
1.00 
1.03 
1.09 
1.14 
1.36 (1.12-1.65) 
Age, region, socioeconomic 
status,  height 
Lin Y et al, 
2007, Japan 
Japanese 
Collaborative 
Cohort Study 
1988/1990 
– 2003, 
12.8 years 
follow-up 
 
Yes, first 3 
years 
excluded 
in 
sensitivity 
analyses 
(not 
shown) 
100932 men 
and women, 
age 40-79 
years: 402 
deaths 
 
Self-reported BMI, men  
 
 
 
 
 
 
BMI, women 
 
 
 
<20.0 
20.0-22.4 
22.5-24.9 
25.0-27.4 
27.5-29.9 
≥30.0 
<20.0 
20.0-22.4 
22.5-24.9 
25.0-27.4 
27.5-29.9 
1.12 (0.76-1.63) 
1.00 
0.94 (0.66-1.34) 
1.02 (0.65-1.62) 
0.62 (0.23-1.70) 
0.58 (0.08-4.16) 
1.15 (0.74-1.80) 
1.00 
1.33 (0.91-1.95) 
1.21 (0.77-1.92) 
1.57 (0.86-2.86) 
Age, cigarette smoking, 
history of diabetes, history of 
gallbladder diseases 
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≥30.0 1.04 (0.37-2.89) 
Lee IM et al, 
2003, USA 
The College 
Alumni Health 
Study 
1962 or 
1966 – 
1995, up to 
34 years 
follow-up  
No  32687: 212 
deaths 
1962-1995  
men and 
women 
Self-reported BMI <22.5 
22.5<25.0 
25.0<27.5 
≥27.5 
1.00 
0.84 (0.59-1.22) 
1.08 (0.74-1.57) 
0.99 (0.60-1.62) 
Age, sex, cigarette smoking, 
diabetes mellitus, mutually 
adjustment between physical 
activity components 
Gapstur SM et 
al, 2000, USA 
The Chicago 
Heart 
Association 
Detection 
Project in 
Industry Study 
1967/73 – 
1995, 25 
years 
follow-up 
 
Yes, first 5 
years 
excluded 
in 
sensitivity 
analyses 
(not 
shown) 
20475 men: 
96 deaths 
15183 
women: 43 
deaths 
Age 15-90 
years (mean 
40) 
Measured  BMI 
 
 
 
BMI, men 
 
 
 
BMI, women 
1 
2 
3 
4 
≤24.128  
24.129-26.292 
26.293-28.630 
≥28.631 
≤20.977  
20.978-23.240 
23.241-26.156 
≥26.157 
1.00 
0.48 (0.17-1.36) 
1.09 (0.47-2.51) 
0.73 (0.30-1.80) 
1.00 
1.84 (0.87-3.92) 
1.71 (0.81-3.61) 
3.07 (1.53-6.15)  
1.00 
0.50 (0.18-1.41) 
1.14 (0.49-2.65) 
0.79 (0.32-1.95) 
Age  
 
 
 
Age, postload plasma glucose 
concentration, cigarette 
smoking status 
 
 
 
 
 
 
Figure 1. Flow-chart of study selection 
 
 
32 
 
 
 
 
 
21973hits yielded from multiple electronic 
bibliographic databases and hand-searching 
18394 hits from WCRF 2
nd
 Expert Report 
(≤2005) 
3581 hits from the Continuous Update (1
st
 
January 2006 - 31
st
 January 2011) 
748 full-text articles retrieved and assessed for 
inclusion 
425 publications included in the WCRF systematic 
literature review 
48 publications from prospective studies reporting 
on the association between BMI, WHR or waist 
circumference and pancreatic cancer and potentially 
suitable for inclusion in the meta-analysis 
 
  
 
21245 excluded on the basis of title and abstract 
323 articles excluded for not fulfilling the inclusion 
criteria 
200 did not report on the associations of 
interest (not relevant exposure or outcome, 
mechanistic study, diagnostic study) 
120 did not contain original data 
(articles/commentary/reviews) 
3 full text not retrieved 
19 publications excluded  
        14 duplicate publications 
        4 publications did not provide risk estimates 
        1 publication with <3 categories 
377 publications excluded for reporting on 
exposures other than BMI, WHR or waist 
circumference and pancreatic cancer and/or study 
type other than prospective study 
29 publications included in the dose-response 
analysis of BMI, WHR or waist circumference and 
pancreatic cancer risk 
33 
 
Figure 2. BMI and pancreatic cancer incidence,  linear (per 5 BMI units) and nonlinear dose-
response analyses 
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 Stevens, 2009   1.09 ( 1.03, 1.16)
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 Stolzenberg-Solomon, 2008   1.05 ( 0.98, 1.13)
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 Verhage, 2007   1.23 ( 1.05, 1.45)
 Berrington de Gonzalez, 2006   1.09 ( 0.95, 1.24)
 Samanic, 2006   1.02 ( 0.90, 1.15)
 Kuriyama, 2005   1.06 ( 0.65, 1.70)
 Larsson, 2005, SMC   1.22 ( 0.89, 1.67)
 Larsson, 2005, COSM   1.34 ( 0.94, 1.90)
 Patel, 2005   1.37 ( 1.17, 1.61)
 Rapp, 2005   1.19 ( 0.99, 1.43)
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Figure 3: BMI stratified by smoking status, waist circumference and waist-to-hip ratio and 
pancreatic cancer incidence, nonlinear dose-response analysis 
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Figure 4: BMI and pancreatic cancer mortality, linear (per 5 units) and nonlinear dose-
response analyses 
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Figure 5: Waist circumference and waist-to hip ratio and pancreatic cancer incidence, linear 
dose-response analysis 
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